Fig. 2.

a) NIPT results for the haematological malignancies (n = 11) per Ann Arbor tumour stage at diagnosis. The y-axis represents the number of patients and the x-axis represents the different tumour stages divided into genome-wide (solid bars) and targeted (shaded bar) NIPT. The colours represent the reviewed NIPT results. Genome-wide NIPT was able to raise strong suspicion (orange bars) for all 10 haematological malignancies of all stages during pregnancy, whereas one postpartum diagnosed malignancy was tested normal with targeted NIPT (shaded green bar). See also Supplemental Table S2. Abbreviations: NIPT: Non-invasive prenatal test. b) NIPT results for the solid tumours (n = 54) per tumour stage at diagnosis using the TNM-, FIGO- or WHO classification. The y-axis represent the number of patients and the x-axis the different tumour stages divided into genome-wide (solid bars, n = 43) and targeted (shaded bars, n = 11) NIPT. The colours represent the reviewed NIPT results. NIPT was able to raise suspicion for malignancy only for 6 of 54 solid tumours, 5 of 43 with genome-wide NIPT and 1 of 11 with targeted NIPT. For solid tumours with stage I and II only 1 of 30 genome-wide NIPT results showed suspicion for a malignancy, see also Supplemental Table S2. Abbreviations: NIPT: Non-invasive prenatal test.